Gut-Brain Axis and Its Role in Affective & Neurodegenerative Conditions

Mood disorders such as major depressive disorder (MDD) and bipolar disorder are increasingly understood as systemic neuroimmune conditions rather than purely brain-localized disorders. One of the most influential frameworks supporting this shift is the microbiota-gut-brain axis (MGBA), a bidirectional communication network linking intestinal microbes, immune signaling, endocrine stress pathways, and neural circuits involved in emotion regulation. Contemporary empirical research indicates that inflammation within this axis plays a central role in mood dysregulation, with direct implications for clinical assessment, treatment planning, and patient self-management (Clapp et al., 2017; Foster et al., 2017).

The MGBA connects the gastrointestinal tract and central nervous system through neural (vagus nerve), endocrine (hypothalamic-pituitary-adrenal [HPA] axis), immune, and metabolic pathways. Within this network, intestinal microbes regulate immune activation and produce metabolites that influence neurotransmission and neuroinflammation. Disruptions in the gut microbiome (dysbiosis) can increase intestinal permeability, allowing microbial products such as lipopolysaccharide (LPS) to enter circulation and activate systemic inflammation. These inflammatory signals can subsequently alter neural circuits involved in emotion regulation and stress responsivity (Cryan et al., 2019; Ramadan et al., 2025; Zeng et al., 2025).

Inflammation is therefore a key mediator linking gut health and mood. Individuals with depression consistently demonstrate elevated pro-inflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), which may reduce serotonin synthesis, increase glutamatergic excitotoxicity, impair hippocampal neurogenesis, and contribute to fatigue and anhedonia (Miller & Raison, 2016; Zhu et al., 2025). Additionally, microbial metabolites such as short-chain fatty acids (SCFAs) normally help maintain blood-brain barrier integrity and regulate microglial activation; reduced SCFA production in dysbiosis may therefore permit greater neuroinflammatory signaling and neuronal vulnerability (Mehta et al., 2025).

From a clinical perspective, this evidence suggests that mood symptoms may partly reflect systemic inflammatory processes originating in the gut. This may help explain why depression commonly co-occurs with gastrointestinal disorders and other inflammatory conditions. For example, approximately 27% of individuals with irritable bowel syndrome (IBS) meet criteria for depression, rates substantially higher than those observed in the general population (Tarar et al., 2023).

Clinical Assessment Implications

Recognition of the gut-brain axis expands the scope of psychiatric and neuropsychological assessment. Clinicians evaluating mood disorders should consider factors that influence gut inflammation and microbiome balance.

1. Screen for gastrointestinal and inflammatory conditions: Conditions such as irritable bowel syndrome, inflammatory bowel disease, celiac disease, and food sensitivities are associated with altered microbiota and increased systemic inflammation, which may exacerbate mood symptoms.
2. Assess lifestyle factors affecting gut health: Diet quality, antibiotic exposure, sleep, alcohol use, and chronic stress all influence microbial diversity and inflammatory signaling. Patients with depression often show reduced dietary diversity and increased ultra-processed food intake-patterns associated with dysbiosis (Jacka et al., 2017).
3. Consider inflammatory phenotypes of depression: Emerging models describe a subset of patients with “inflammatory depression,” characterized by elevated cytokines, fatigue, anhedonia, and treatment resistance. These individuals may be particularly sensitive to gut-related inflammatory mechanisms (Miller & Raiso, 2016).
4. Evaluate medication-gut interactions: Psychotropic medications can alter microbiota composition, while gastrointestinal conditions can influence medication absorption and metabolism. For example, inflammation-related changes in gut permeability may affect pharmacokinetics and treatment response (Jacka et al., 2017). Clinicians should therefore consider gastrointestinal symptoms and dietary patterns when evaluating medication efficacy and side effects.

Treatment Implications: Integrating Gut-Focused Strategies

Although microbiome interventions are not stand-alone psychiatric treatments, accumulating evidence supports their role as adjunctive strategies targeting inflammation and neuroimmune regulation.

Nutrition and Anti-Inflammatory Diets

Diet is among the most powerful and modifiable regulators of the microbiota-gut-brain axis (MGBA). Nutritional patterns directly influence gut microbial diversity, intestinal permeability, systemic inflammation, immune signaling, and neurotransmitter synthesis, all of which are implicated in mood regulation and psychiatric functioning (Cryan et al., 2019; Marx et al., 2021). Increasing evidence suggests that dietary factors may either exacerbate neuroinflammatory processes associated with depression and anxiety or support neuroprotective and anti-inflammatory pathways that promote emotional wellbeing.

Western-style dietary patterns characterized by high consumption of ultra-processed foods, refined carbohydrates, processed meats, saturated fats, trans fats, and sugar-sweetened beverages have consistently been associated with increased inflammatory burden and greater risk for depressive symptoms (Lassale et al., 2019). Diets high in refined sugars and processed foods may reduce microbial diversity and increase intestinal permeability, sometimes referred to as “leaky gut,” thereby allowing inflammatory bacterial products such as lipopolysaccharide (LPS) to enter systemic circulation and activate pro-inflammatory cytokine cascades (Foster et al., 2017; Miller & Raison, 2016). Chronic inflammation may subsequently affect serotonin metabolism, glutamatergic signaling, hypothalamic-pituitary-adrenal (HPA) axis functioning, and hippocampal neurogenesis, all of which are implicated in mood disorders (Miller & Raison, 2016).

Particular attention has been given to diets high in processed and red meats, fried foods, excessive alcohol consumption, and highly refined carbohydrates, which have been associated with increased levels of inflammatory biomarkers including interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor-alpha (TNF-α) (Adjibade et al., 2019). Excessive intake of these foods may also contribute to obesity, insulin resistance, metabolic syndrome, and cardiovascular disease, all of which independently increase risk for depression and cognitive dysfunction.

Conversely, anti-inflammatory dietary patterns such as the Mediterranean diet appear to support MGBA functioning and emotional health through multiple biologic pathways. Mediterranean-style diets are rich in fiber, fruits, vegetables, legumes, nuts, seeds, olive oil, whole grains, fish, and fermented foods, while being relatively low in processed foods and refined sugars. These diets promote microbial diversity and increase production of short-chain fatty acids (SCFAs), including butyrate, acetate, and propionate, which help regulate microglial activation, maintain blood-brain barrier integrity, and reduce systemic inflammation (Mehta et al., 2025).

Omega-3 fatty acids found in fatty fish such as salmon, sardines, mackerel, trout, and tuna have been particularly associated with anti-inflammatory and neuroprotective effects. Omega-3 fatty acids influence neuronal membrane fluidity, neurotransmitter functioning, and inflammatory signaling, and lower omega-3 levels have been repeatedly associated with depressive symptomatology (Grosso et al., 2014). Similarly, foods rich in vitamin D, including fatty fish, fortified dairy products, egg yolks, and mushrooms, which may support immune regulation and mood stability, as vitamin D deficiency has been linked to depression, fatigue, and cognitive complaints (Vellekkatt & Menon, 2019).

Fermented foods such as yogurt, kefir, kimchi, sauerkraut, miso, and kombucha may additionally support gut microbial diversity by introducing beneficial bacterial strains. Emerging evidence suggests that probiotic and fermented-food interventions may modestly reduce depressive and anxiety symptoms through immune modulation, vagal signaling, and regulation of neurotransmitter synthesis (Nikolova et al., 2021; Zhu et al., 2025). Diets rich in prebiotic fibers including oats, bananas, asparagus, garlic, onions, lentils, and beans,may further support growth of beneficial gut bacteria associated with anti-inflammatory effects.

Importantly, the relationship between nutrition and mood appears bidirectional. Depression itself may contribute to reduced motivation, emotional eating, irregular meal patterns, and increased reliance on highly processed convenience foods, which may further worsen inflammatory burden and dysbiosis. Chronic stress additionally alters gut microbiota composition and intestinal permeability through HPA-axis activation, thereby perpetuating a reciprocal gut-stress-inflammation cycle (Ruohan et al., 2025).

From a clinical standpoint, these findings highlight the importance of incorporating dietary assessment into psychiatric and neuropsychological care. Mental health professionals should consider evaluating nutritional quality, gastrointestinal symptoms, inflammatory risk factors, and lifestyle behaviors as part of comprehensive biopsychosocial assessment. Although dietary interventions should not replace evidence-based psychiatric treatment, accumulating evidence supports the role of anti-inflammatory and gut-supportive nutritional strategies as meaningful adjunctive interventions for some individuals with mood disorders, particularly those with inflammatory features, metabolic dysfunction, gastrointestinal comorbidity, or treatment-resistant depression.

Probiotics

Certain probiotic strains have demonstrated modest improvements in depressive and anxiety symptoms and increased brain-derived neurotrophic factor (BDNF) in clinical populations (Zhu et al., 2025). These effects are thought to occur through immune modulation, neurotransmitter regulation, and HPA-axis normalization. While evidence is still emerging, probiotics may be considered as adjunctive interventions, particularly in patients with gastrointestinal comorbidity or inflammatory features.

Stress Reduction and the Gut-Stress Loop

Chronic stress alters microbiota composition and increases intestinal permeability, amplifying inflammatory responses. Conversely, dysbiosis can heighten stress sensitivity through HPA-axis dysregulation (Ruohan et al., 2025). Stress-reduction interventions including mindfulness, exercise, and sleep regulation, have both psychological and gut-mediated benefits.

Physical Activity

Exercise increases microbial diversity and anti-inflammatory metabolites, in addition to its established antidepressant effects. This dual mechanism highlights the gut-brain axis as one pathway through which physical activity may improve mood and emotional functioning (Allen et al., 2018; Kandola et al., 2019).

In summary, growing and contemporary evidence from neuroimmune and microbiome research highlights how mood disorders such as depression and bipolar disorder are best understood through an integrated biopsychosocial and systemic framework, rather than solely from a neurotransmitter-based framework. For clinicians, this paradigm shift underscores the importance of comprehensive assessment that includes gastrointestinal health, inflammatory risk factors, lifestyle behaviors, and medication-gut interactions. While gut-focused interventions such as dietary modification, physical activity, stress reduction, and selected probiotic use should not replace established psychiatric treatments, they represent meaningful adjunctive strategies that target underlying neuroinflammatory mechanisms.

Clinical Takeaways for Mental Health Professionals

The gut–brain axis has several practical implications for clinical practice:

• Mood symptoms may reflect systemic inflammation. Depression should not be conceptualized solely as a neurotransmitter disorder; immune and metabolic contributors may be present.
• Gastrointestinal health is relevant to psychiatric care. Screening for gut symptoms and dietary patterns can inform treatment planning.
• Inflammation may contribute to treatment resistance. Patients with inflammatory features may respond differently to conventional antidepressants and benefit from adjunctive anti-inflammatory strategies.
• Lifestyle interventions are biologically meaningful. Nutrition, sleep, and stress management influence neuroimmune pathways central to mood regulation. Integrated treatment models are warranted. Collaboration across disciplines may improve outcomes in mood disorders with systemic components.

Resources for Future Learning:

Harvard Health – Foods That Fight Inflammation

National Center for Complementary and Integrative Health – Probiotics Overview

Mediterranean Diet Overview – American Heart Association